NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences announced a quarterly dividend on Wednesday, July 25th. Shareholders of record on Friday, September 14th will be given a dividend of $0.57 per share on Thursday, September 27th. This represents a $2.28 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date of this dividend is Thursday, September 13th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Wednesday, July, 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.56 by $0.35. The biopharmaceutical company earned $5.65 billion during the quarter, compared to analysts' expectations of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. Gilead Sciences's quarterly revenue was down 20.9% on a year-over-year basis. During the same period last year, the firm earned $2.56 EPS. View Gilead Sciences' Earnings History.

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Gilead Sciences.

24 Wall Street analysts have issued 12 month price targets for Gilead Sciences' stock. Their predictions range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' stock price to reach $87.9414 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 10 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

Gilead Sciences saw a increase in short interest in the month of July. As of July 13th, there was short interest totalling 15,410,952 shares, an increase of 12.5% from the June 29th total of 13,701,705 shares. Based on an average daily volume of 6,413,971 shares, the short-interest ratio is currently 2.4 days. Currently, 1.2% of the shares of the company are sold short. View Gilead Sciences' Current Options Chain.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO) and Crispr Therapeutics (CRSP).

News headlines about GILD stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gilead Sciences earned a news impact score of 0.20 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Gilead Sciences.

Gilead Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.12%), Bank of New York Mellon Corp (2.38%), FMR LLC (1.51%), Parnassus Investments CA (1.50%), Sanders Capital LLC (0.81%) and Boston Partners (0.64%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Bank of Nova Scotia, Caisse DE Depot ET Placement DU Quebec, American Century Companies Inc., ANTIPODES PARTNERS Ltd, Oppenheimer & Co. Inc. and Morgan Stanley. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

GILD stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Natixis, Los Angeles Capital Management & Equity Research Inc., Sanders Capital LLC, Unigestion Holding SA, Diamond Hill Capital Management Inc., Envestnet Asset Management Inc. and Janus Henderson Group PLC. View Insider Buying and Selling for Gilead Sciences.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GILD stock can currently be purchased for approximately $72.36.

Gilead Sciences has a market capitalization of $99.47 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]